Abstract
The setup of tumorigenesis processes is generally associated with various events leading to abnormal expression of oncogenes and/or tumor suppressor genes. Recently, the expression and/or activity of a range of molecules involved in these processes were reported to require proteolytic processing of their precursor proteins by the serine proprotein convertases (PCs) in order to mediate their biological functions. These include adhesion molecules, proteases, growth factors, cytokines and their receptors. Since their discovery, the identification of new PCs substrates and specific PCs inhibitors became an attractive strategy in cancer therapy. In this review, we will report the implication of these enzymes and the processing of their substrates in tumor progression and metastasis. Newly reported studies on the potential use of the PCs as new therapeutic targets will be also discussed.
Keywords: Proprotein Convertases, furin, PACE4, PC5, PC7, cancer, metastasis, inhibitors, prosegments
Recent Patents on Anti-Cancer Drug Discovery
Title: The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Volume: 4 Issue: 1
Author(s): Rachid Lahlil, Fabien Calvo and Abdel-Majid Khatib
Affiliation:
Keywords: Proprotein Convertases, furin, PACE4, PC5, PC7, cancer, metastasis, inhibitors, prosegments
Abstract: The setup of tumorigenesis processes is generally associated with various events leading to abnormal expression of oncogenes and/or tumor suppressor genes. Recently, the expression and/or activity of a range of molecules involved in these processes were reported to require proteolytic processing of their precursor proteins by the serine proprotein convertases (PCs) in order to mediate their biological functions. These include adhesion molecules, proteases, growth factors, cytokines and their receptors. Since their discovery, the identification of new PCs substrates and specific PCs inhibitors became an attractive strategy in cancer therapy. In this review, we will report the implication of these enzymes and the processing of their substrates in tumor progression and metastasis. Newly reported studies on the potential use of the PCs as new therapeutic targets will be also discussed.
Export Options
About this article
Cite this article as:
Lahlil Rachid, Calvo Fabien and Khatib Abdel-Majid, The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489209787002470
DOI https://dx.doi.org/10.2174/157489209787002470 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
Current Drug Metabolism The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
Current Cancer Drug Targets Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Targeting PPARalpha in Alzheimer's Disease
Current Alzheimer Research Recent Developments of 18F-FET PET in Neuro-oncology
Current Medicinal Chemistry Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets The Pathophysiological Role of PEDF in Bone Diseases
Current Molecular Medicine Transposons for Gene Therapy!
Current Gene Therapy Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Suramin: Clinical Uses and Structure-Activity Relationships
Mini-Reviews in Medicinal Chemistry Extracorporeal Shock Wave Therapy in Inflammatory Diseases: Molecular Mechanism that Triggers Anti-Inflammatory Action
Current Medicinal Chemistry Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology